Advertisement

Topics

Latest Clostridium difficile (CDI) NewsRSS

11:49 EST 21st November 2018 | BioPortfolio

Assembly Biosciences Inc ASMB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryAssembly Biosciences Inc Assembly, formerly Ventrus Biosciences Inc is a biotechnology company that develops, discovers, and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as microbiotic therapies for Clostridium difficile C. difficile infections CDI and chronic hepatitis B virus HBV. It also develops Gemicel platform te...

MALADIE de CROHN : Un nouveau marqueur pour mieux cibler le traitement

La maladie de Crohn (MC), une maladie inflammatoire chronique du tractus intestinal, est en augmentation constante depuis ces 50 dernières années. Alors que la condition réunit, selon les experts, un ensemble de troubles liés mais légèrement différents, identifier avec précision le sous-type de la maladie restait un défi. Cette équipe de l'Université Cornell (New York) […]

AMBLYOPIE : Une vision anormale pendant l'enfance peut affecter les fonctions cérébrales

Une vision anormale pendant l'enfance peut affecter les fonctions cérébrales supérieures, comme l’attention, révèle cette étude de l’Université de Waterloo (Canada). Chez ces enfants atteints de différents types de paresse oculaire, les chercheurs constatent en effet des différences dans la façon dont le cerveau traite l'information visuelle. L’étude, présentée dans la...

INCONTINENCE MASCULINE : Le choix du palliatif

  L’utilisation de protections absorbantes représente aujourd’hui la solution palliative la plus courante, après échec des différents traitements et interventions comportementales. Le choix des palliatifs et leur présentation au patient fait partie du projet de soin à définir par le soignant en fonction du projet de vie du patient ou du résident. Alors que les […]

Mobidiag Receives Final €4M Tranche of €15M EIB Financing

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, announced today that it has received the final €4M tranche of a €15M three-year project secured by the Company from the European Investment Bank Group (EIB) in July 2016. The loan was provided as part of “InnovFin – EU Finance for inno...

Oragenics, Inc. Announces 3Q 2018 Financial Results and Provides Corporate Update

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced financial results for the quarter ended September 30, 2018. As of September 30, 2018, the Company reported $13.8 million in cash, compared to $6.2 million as of December 31, 2017. ...

Sanimed & Xenex Deploy Pulsed Xenon UV Disinfection Technology to Battle Superbugs at Victor Babes Hospital in Romania

As hospitals around the world look for strategies to combat healthcare associated infections and antibiotic resistance, Sanimed International and Xenex Disinfection Systems have brought Xenex’s world class room disinfection technology to Romania. Healthcare a

SCOLIOSE : Les minéraux essentiels en question

Dans de nombreux cas, les enfants atteints de scoliose ne présentent aucun facteur de risque connu. Et les facteurs génétiques restent encore mal connus. Les cas de scoliose ont tendance à se regrouper au sein des familles, mais pas de manière simple, ce qui suggère que de nombreux gènes différents pourraient jouer chacun un petit […]

Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET. A live audio webcast of the presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximate...

STRESS : Le gène qui allège le stress social et alourdit le stress financier

C’est la découverte d’un gène de risque de stress, mais ambivalent, qui vient éclairer le développement de la dépression, en raison de différents facteurs, sociaux ou financiers : car ce même gène a un effet protecteur lorsqu’il s’agit de facteurs sociaux et aggravant lorsqu’il s’agit de facteurs financiers. Des conclusions présentées au 31è Congrès du Collège […]

Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates

- Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two new microbiome clinical studies in ulcerative colitis and metastatic melanoma; Company expects to receive $40M in payments from Nestlé Health Science with SER-287 Phase 2b study start - - Conference call at 8:30 ...

MGB Biopharma Ltd Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryMGB Biopharma Ltd MGB Biopharma is a a biopharmaceutical company which develops novel class of antiinfectives using Minor Groove Binder MGBs compounds. Its lead drug candidate MGBBP3 in the field of antibacterial resistance is active against may Grampositive bacteria. MGB Biopharma also developed an oral formulation of MGBBP3 for Clostridium difficile. The company's technology platform prov...

Bacterial Therapy May Be Promising in Cancer Patients

Dr. Filip Janku speaks with Cancer Network about a phase I clinical trial investigating the use of bacterial clostridium novyi-NT in solid tumors.

Rash induced by enteral vancomycin therapy in an older patient in a long-term care ventilator unit: case report and review of the literature

Oral vancomycin is a first-line treatment for severe Clostridium difficile colitis. Oral vancomycin is perceived to lack systemic absorption or systemic adverse effects; however, a few cases of hypersensitivity t...

Scioto Biosciences Presents Single-dose, Single Strain Pre-clinical C. diff Intervention at American Academy of Pediatrics National Conference & Exhibition

“A Novel Probiotic Platform Therapy for the Treatment of Clostridium difficile Infection” Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced the presentation of data showing significant reduction of incidence

Seres Therapeutics Inc MCRB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummarySeres Therapeutics Inc Seres, is a microbiome therapeutics platform company that develops a novel class of biological drugs. The company creates a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. The company's lead development candidate, SER109 is an oral microbiome therapeutic and bacterial spore ecology that...

Valneva SE VLA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryValneva SE Valneva is a biotech company that develops lifesaving vaccines. The company's products include IXIARO, a vaccine indicated for the prevention of Japanese encephalitis; and Dukoral, a vaccine indicated for the prevention of cholera and diarrhea; clostridium difficile, lyme, chikungunya, and zika diseases. It provides EB66 cell line, a proprietary embryonic stem cellbased technolog...

Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018

Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on November 8, 2018 at 8:30 a.m. ET to discuss third quarter 2018 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and refe...

Clostridium difficile Infections Clostridium difficile Associated Disease Pipeline Review, H2 2018 [Report Updated: 30102018] Prices from USD $2000

Clostridium difficile Infections Clostridium difficile Associated Disease Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections Pipeline Review, H2 2018, provides an overview of the Clostridium difficile Infections Infectious Disease pipeline landscape.Clostridium difficile infections are caused by Clos...

Global C Difficile Infection Drug Market Status and Outlook 20182025 [Report Updated: 16082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month

Proclamation heightens public awareness and impact of the devastating infection. Rebiotix Inc, a late-stage biotechnology focused on harnessing the power of the microbiome to treat debilitating diseases, joined the C. Diff Foundation today to congratulate the State of Minnesota for declaring November “Clostridium difficile Awareness...

Summit Recognises C. difficile Awareness Month

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit Recognises C. difficile Awareness Month Oxford, UK, and Cambridge, MA, US, 1 November 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, recognises C. difficile Awareness Month, which highlights the common, but largely unknown C. difficile infection (CDI) thro...

Sequella Inc Medical Equipment Deals and Alliances Profile [Report Updated: 15102018] Prices from USD $250

SummarySequella Inc Sequella is a clinicalstage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company's pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, BSMART. Sequella develops antibodies for infections such as mycobacterium tuberculosis, helicobacter pylori, clost...

Clostridium difficile infection perceptions and practices: a multicenter qualitative study in South Africa

Clostridium difficile infection (CDI) is understudied in limited resource settings. In addition, provider awareness of CDI as a prevalent threat is unknown. An assessment of current facilitators and barriers to C...

ENVIRONNEMENT : Peut-il affecter notre Q.I. ?

Précisément, un environnement de vie donné peut-il entraîner des modification épigénétiques au niveau de notre cerveau ? L’expression des gènes du cerveau est-elle sensible à ce type d’exposition ? Cette étude de la Charité – Universitätsmedizin Berlin révèle, sans surprise, ce lien entre les différences de performances des tests de QI et l'activité de certains gè...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Clostridium difficile (CDI) market research data and corporate reports here